JLJaims Lim

Jaims Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaims Lim has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Atlas self-expandable stents versus low profile visualized intraluminal support stents for intracranial aneurysm coiling assistance: systematic review and meta-analysis

    by Vinay Jaikumar, Laz S Rifkin, Patrick M Wahlig, Taysia P T Morioka, Aditya D Goyal, Julia Rupp, Isabelle G Stockman, Liam Levy, Lukasz Przepiorka, Andre Monteiro, et al.

    Background: Neurointerventionalists performing stent assisted coil embolization for intracranial aneurysms use Neuroform Atlas stents (Stryker) for their low metal coverage, deployment ease, and lower thromboembolic risk, although low profile visualized intraluminal support (LVIS) and LVIS Jr stents (Terumo Neuro) offer better wall apposition and high metal coverage, potentially promoting flow diversion and endothelialization. The next generation LVIS Evolution (LVIS EVO; Terumo Neuro) adds enhanced visibility, improved resheathability, and even higher metal coverage to address earlier limitations of LVIS and LVIS Jr. We evaluated the performance and complications of these devices. Methods: PubMed and Embase were searched from 1 January 2017 to 31 July 2025 to identify studies comparing Atlas assisted coil embolization (AACE) versus LVIS/LVIS Jr assisted coil embolization (LACE), and single arm LVIS EVO assisted coil embolization (LeACE) studies. Meta-analyses were performed to compare baselines, procedural considerations, and occlusion rates. Results: We included five studies comparing 504 patients treated with AACE and 579 patients with LACE, and 12 studies evaluating LeACE (575 patients). Fewer aneurysms were ruptured at presentation in the AACE group than in the LACE (OR 0.09; P<0.01) and LeACE (0.7% vs 15.2%; P<0.01) groups. Comparable technical failure rates were found between AACE and LeACE (1.8% vs 5.4%; P=0.15), contrasting with the superiority of AACE over LACE (OR 0.14; P<0.01). AACE resulted in higher immediate adequate occlusion than LACE (OR 1.62; P=0.02), but comparable with LeACE (83% vs 90.8%; P=0.28). Follow-up complete occlusion rates were similar between AACE and LACE (OR 1.31; P=0.16) and between AACE and LeACE (82.4% vs 81.2%; P=0.86). Conclusions: The superior outcomes of the Atlas over LVIS/LVIS Jr were matched by the LVIS EVO. Thromboembolic complications occurred more frequently with the LVIS EVO.

  • Open Access

    Implementation and clinical utility of ultra-low-field portable magnetic resonance imaging for postprocedural neurological evaluation in ambulatory neurosurgery: illustrative cases

    by Devan Patel, Vinay Jaikumar, Taysia P. T. Morioka, Laz Rifkin, Kenneth S. Jacoby, Jaims Lim, Anais Andrade, Aimee C. DeGaetano, Pui Man Rosalind Lai, Elad I. Levy

    BACKGROUND: Elective endovascular neurosurgical procedures are increasingly performed in ambulatory neurosurgery centers, enabled by advances in catheter technology, safety of conscious sedation, and refined patient selection. Although complication rates are low, rapid evaluation of postprocedural neurological deficits remains critical. Conventional MRI is often impractical in outpatient or procedural settings, whereas ultra-low-field portable MRI (ULF-pMRI) systems (such as Swoop) allow bedside imaging with favorable diagnostic performance. OBSERVATIONS: Two women in their 60s developed acute neurological deficits at an ambulatory neurosurgery center (ANSC) after diagnostic cerebral angiography in one case and elective internal carotid artery flow diversion in the other. In both cases, repeat angiography showed patent vessels. Bedside ULF-pMRI with diffusion-weighted and fluid-attenuated inversion recovery sequences demonstrated no acute infarction or hemorrhage. Symptoms fully resolved with supportive management. The availability of rapid portable MRI helped both patients avoid hospital admission, allowing same-day discharge without recurrent neurological symptoms. LESSONS: In these 2 cases, ULF-pMRI demonstrated timely, informative neuroimaging in an ANSC setting. When paired with clinical improvement, bedside MRI safely guided disposition decisions, helped avoid unnecessary transfers, and supported patient safety as outpatient neurointervention expands. https://thejns.org/doi/10.3171/CASE26245

  • Open Access

    Penetrating brain injury with a nail gun: technical considerations and the role of cerebral angiography. Illustrative case

    by Devan Patel, Sanjida Riea, Alexander G. Fritz, Jaims Lim, Ryan M. Hess, Hamid S. Khan, Elad I. Levy, Kenneth V. Snyder, Hanna N. Algattas

    BACKGROUND: Nail gun injuries are rare forms of penetrating brain injuries that can be associated with significant morbidity and mortality. Management strategies differ greatly in previously reported cases. OBSERVATIONS: A male in his 40s presented with an accidental, work-related nail gun injury to the left parietal lobe with no focal neurological deficits. Noncontrast CT imaging of the head and vessel imaging including CT angiography and venography were performed that demonstrated the retained nail with trace surrounding intraparenchymal hemorrhage but no obvious vascular injury. The patient underwent a preoperative diagnostic cerebral angiography that confirmed no vascular injury. The patient was then taken to a hybrid operating room/angiography suite for a burr hole craniotomy for nail removal. Selective left internal carotid artery intraoperative angiography was performed to confirm there was no contrast extravasation after nail removal. The patient was discharged home on postoperative day 1 on prophylactic antibiotics. Follow-up angiography did not demonstrate pseudoaneurysm formation. LESSONS: Nail gun injuries require a comprehensive, multidisciplinary approach to minimize the risk of complications, particularly related to vascular injury. Judicious use of preoperative and intraoperative catheter-based angiography can facilitate safe, efficient nail removal and is imperative in assessing immediate and delayed sequelae of penetrating trauma. https://thejns.org/doi/10.3171/CASE25476

  • Multicenter comparative analysis of FRED-X, pipeline shield, and surpass evolve in treating intracranial aneurysms

    by Joanna M. Roy, Basel Musmar, Spyridon Karadimas, Matthews Lan, Sravanthi Koduri, Arbaz Momin, Alana McNulty, Alexandra Paul, Yi Zhang, Ajit S. Puri, et al.

    Background: In recent years, newer flow diverters have been developed with surface modification and varying wire densities. Our study evaluated outcomes among three newer generation flow diverter devices, FRED-X, PED Shield and Surpass Evolve. Methods: This was a retrospective study of patients from five participating institutions across the United States. Patients who underwent flow diversion of intracranial aneurysms using the FRED-X, PED Shield or Surpass Evolve between February 2022 and September 2024 were included. Outcomes of interest were technical success, angiographic occlusion and in-stent stenosis (ISS). Results: Among 447 patients with 452 aneurysms, adjunct device use was highest with Surpass Evolve (36.4%) versus PED Shield (15.7%) and FRED-X (6.4%) ( p < .001). Good wall apposition after angioplasty/stenting was most frequent with Surpass Evolve (32.3%) versus PED Shield (13.7%) and FRED-X (4.5%) ( p < .001). At six months, complete occlusion was achieved in 69.3% (PED Shield), 63.6% (FRED-X), and 58% (Surpass Evolve) ( p = .254). ISS rates were comparable at six months ( p = .826). At 12 months, complete occlusion was observed in 78.9% of PED Shield, 68.4% of FRED-X, and 64.5% of Surpass Evolve aneurysms. Most ISS cases at 12 months were mild. Kaplan-Meier analysis showed no significant difference in occlusion rates ( p = .914). Conclusions: Flow diversion using FRED-X, PED Shield and Surpass Evolve resulted in comparable rates of angiographic occlusion and ISS. However, adjunctive devices were more commonly needed with Surpass Evolve.


  • Revisiting intra-arterial chemotherapy—palliative utility in a case of recurrent esthesioneuroblastoma and literature review

    by Bernard Okai, Jaims Lim, Vinay Jaikumar, Moleca Ghannam, Laszlo L Mechtler, Kunal Vakharia, Adnan H Siddiqui, Elad I Levy

    Background: Esthesioneuroblastomas (ENBs) are rare, aggressive tumors arising from the olfactory neuroepithelium in the superior nasal tract. Current treatment strategies typically involve a combination of surgery and radiation, with systemic chemotherapy considered on a case-by-case basis. However, the role of intra-arterial (IA) therapies for ENBs remains underexplored. In this report, we present an illustrative case from our center and a systematic literature review compiling an overview of similar cases. Methods: The case of an elderly man with recurrent ENB treated with IA carboplatin is described. We systematically reviewed PubMed and Embase to gather data on the indications, treatment course, and outcomes of IA chemotherapy for ENBs. Results: The patient presented initially with epistaxis and was diagnosed with ENB post-resection and radiation. Recurrence occurred 28 years later, causing visual loss and headaches. Multiple sessions of stereotactic radiosurgery over 2 years were ineffective. After multispecialty discussions, IA carboplatin was selected for neoadjuvant therapy. The bilateral internal maxillary arteries (IMAs) were identified as primary feeders of the recurrence. Carboplatin was directly administered via the IMAs in two stages, 1 month apart. The procedures were well-tolerated, and the patient was discharged without complications. Despite symptom improvement with radiographically stable tumor at 2-month follow-up, the patient opted for palliative care. The systematic review identified four ENB cases involving the ethmoid sinus with varying extensions into anterior and middle cranial fossae. IA chemotherapeutics were administered through maxillary or carotid arteries as an adjunct to resection, radiotherapy, or systemic chemotherapy, with no intraprocedural or postprocedural complications reported. Two patients died during follow-up: one with primary ENB and another with recurrent ENB. Conclusion: The safe administration of IA chemotherapeutics for primary and recurrent ENB in this case and literature review suggests a potential role for IA therapies in managing intracranial tumors, especially with advanced superselective microcatheter techniques.


  • Effectiveness of subdural evacuating port system (SEPS) and middle meningeal artery embolization (MMAE) for chronic subdural hematomas – a multicenter experience

    by Jaims Lim, Vinay Jaikumar, Alexandra R Paul, Matthew Cullen, Christopher P Kellner, J Mocco, Brandon D Philbrick, Kunal Vakharia, Patrick Wahlig, Marissa D Kruk, et al.

    Background Craniotomy for subdural hematoma (SDH) in elderly patients with comorbidities can be challenging. The Subdural Evacuating Port System (SEPS; Medtronic, Minneapolis, MN) offers a less invasive alternative, while middle meningeal artery embolization (MMAE) has shown effectiveness in preventing SDH recurrence. We evaluated the combined effectiveness of SEPS+MMAE for chronic SDH (cSDH) treatment. Methods Retrospective database reviews were conducted. Demographic, comorbidity, procedural, and outcomes data were analyzed. cSDH resolution was tracked by measuring hematoma volumes on noncontrast computed tomograms pre-SEPS+MMAE, 24–48 hours post-SEPS+MMAE, and 6–8 weeks afterward (follow-up-SEPS+MMAE). Results Our study included 114 patients (median age: 77 years (interquartile range (IQR): 69–83 years); men: women=74:40) with 134 cSDHs treated with SEPS+MMAE were included. Median pre-SEPS+MMAE cSDH volume was 122.9 mL (88–152.4 mL) with midline shift of 6 mm (3.4–9.5 mm). Most MMAE procedures were performed under general anesthesia (68.7%), utilizing the femoral approach (61.9%) and particle embolic agents (55.2%). In-hospital rescue craniotomy was required after 10 (7.5%) procedures. Median post-SEPS+MMAE and follow-up-SEPS+MMAE cSDH volume reductions were 71.1 mL (54.1–94.8 mL) and 23.4 mL (2–56.3 mL), respectively, resulting in 38.1% (22.1–52.9%) and 79.9% (51–97.8%) reductions, respectively. Of 109 patients with follow-up, 10 (9.2%) were readmitted for cSDH residual/recurrence within 90 days, eight (7.3%) required retreatment: five (4.6%) with craniotomy, three (2.8%) with SEPS. Hyperlipidemia (P=0.002), anticoagulant use (P=0.036), and larger pre-SEPS+MMAE cSDH volume (PConclusion SEPS+MMAE was an effective, safe treatment for cSDH.


  • Effectiveness of subdural evacuating port system (SEPS) and middle meningeal artery embolization (MMAE) for chronic subdural hematomas

    by Vinay Jaikumar, Jaims Lim, Patrick Wahlig, Matthew K Moser, Julia Rupp, Marissa D Kruk, Muhammad Waqas, Devan Patel, Alexander G Fritz, Andre Monteiro, et al.

    Background: Performing a craniotomy for chronic subdural hematoma (cSDH) in elderly patients with comorbidities can be challenging. The Subdural Evacuating Port System (SEPS; Medtronic, Dublin, Ireland) offers a less-invasive alternative, while middle meningeal artery embolization (MMAE) has shown effectiveness in preventing cSDH recurrence. However, the combined effectiveness of SEPS and MMAE (SEPS + MMAE) remains unclear. This study reports the outcomes of patients undergoing a combination of these procedures for the treatment of cSDH. Methods: A retrospective review of our medical records database was conducted to identify patients with cSDH who were treated with SEPS + MMAE between January 1, 2021, and April 1, 2024. Demographics, comorbidities, procedure, and outcomes data were analyzed. cSDH resolution was tracked by measuring hematoma volumes on noncontrast computed tomography scans pre-SEPS + MMAE, 24–48 h postprocedure, and 6–8 weeks postprocedure. Results: A total of 35 patients (median age: 77 years [interquartile range (IQR):69–85.5]; men:woman = 22:13) with 49 cSDH, of which 41 cSDHs receiving combined SEPS + MMAE were included. Notably, 38 (92.7%) of the 41 cSDHs were holohemispheric, and 15 (36.6%) had an acute or subacute component. The median pre-SEPS + MMAE cSDH volume was 121.9 mL [IQR:87.9–153.4 mL] with a median midline shift of 6.6 mm [IQR:3.5–10 mm]. All MMAE procedures were performed under conscious sedation. The femoral approach was utilized in 19 patients (54.3%). Three patients required rescue craniotomy. Median post-SPES + MMAE volume was 71.1 mL [IQR:54.5–93.2], resulting in a 38% [IQR:21.9–53] reduction in cSDH volume; and median follow-up SEPS + MMAE volume was 22 mL [IQR:2–59.2] resulting in an 81% [IQR:50.9–98.1] reduction in cSDH volume, compared to pre-SEPS + MMAE levels. Seven (17.1%) patients required readmission for residual or recurrent cSDH within 90 days. Five of these patients were retreated (12.2%), two of whom required craniotomy (4.9%). Conclusion: Our experience suggests that SEPS + MMAE was an effective method of cSDH treatment and was associated with low complication rates.


  • Open Access

    Adult-onset medulloblastoma presenting in the setting of untreated spina bifida: illustrative case

    by Devan Patel, Sanjida Riea, Jaims Lim, Hamid S. Khan, Lauren Gugino, Chloe Carver, Kenneth V. Snyder, Hanna N. Algattas

    BACKGROUND: Adult-onset medulloblastoma in the setting of untreated spina bifida and Chiari type II malformation is exceptionally rare and has not been previously reported. The relationship between medulloblastoma and spina bifida remains poorly understood. OBSERVATIONS: An adult male with untreated spina bifida presented to the emergency department with headaches and was found to have a left cerebellar medulloblastoma and obstructive hydrocephalus. He underwent preoperative catheter-based angiography, which revealed inferior displacement of the venous sinuses. A suboccipital craniotomy for resection was performed, followed by radiation therapy and chemotherapy. Follow-up imaging at 3 months postoperatively demonstrated no evidence of residual tumor. LESSONS: Given the abnormal posterior fossa development in patients with spina bifida and Chiari type II malformation, posterior fossa surgery requires a thorough understanding of the patient’s venous sinus anatomy to achieve a maximal safe resection and prevent venous sinus injury or thrombosis. While the role of CSF diversion in adults with untreated spina bifida is unknown, the authors opted to proceed with postresection ventriculoperitoneal shunt placement given the persistent mass effect on the fourth ventricle from peritumoral swelling. Additional studies are needed to establish a molecular and/or genetic relationship between medulloblastoma and spinal dysraphism. https://thejns.org/doi/10.3171/CASE24897

  • Addressing residual and recurrent aneurysms post-Woven EndoBridge device embolization: a systematic review and meta-analysis

    by Vinay Jaikumar, Jaims Lim, Matthew D Moser, Bernard Okai, Hendrick Francois, Ana E Cadar, Muhammad Waqas, Andre Monteiro, Pui Man Rosalind Lai, Jason M Davies, et al.

    Background Early literature on the Woven EndoBridge (WEB) device reported 80–90% adequate aneurysm occlusion but low complete occlusion (40–55%). It is uncertain whether residual or recurrent aneurysms require re-treatment to prevent future rupture. Objective To systematically review the literature to meta-analyze occlusion and complication rates after re-treatment of these aneurysms. Methods PubMed and EMBASE were queried for ‘re-treatment’ of ‘recurrent’ or ‘residual’ aneurysms treated with the WEB device. Studies reporting strategies and outcomes were included. Patient and aneurysm characteristics, outcomes, and complications were extracted. Meta-analyses were conducted on variables reported by three or more studies. Results We included 15 studies of 220 patients (220 aneurysms) with a mean age of 57.8 years (95% CI 55.1 to 60.7 years). At baseline, 42.8% (95% CI 35% to 51%) of aneurysms were ruptured, had a mean 8.6 mm dome (95% CI 7.3 to 10 mm) and a mean 5.2 mm neck (95% CI 4.7 to 5.7 mm), and 69.85% were at bifurcations (95% CI 47.63% to 85.51%). At mean 11.2 months' follow-up (95% CI 8 to 15.6 months), 75.9% (95% CI 66.1% to 83.5%) had residual dome filling, predominantly from incomplete occlusion in 84.7% of cases (95% CI 66.6% to 93.9%). Endovascular management was used in 82.5% (95% CI 72.6% to 89.3%) of recurrences, with stent-assisted or flow diverter-assisted coil embolization being used in 42.4% (95% CI 32.7% to 52.8%). Overall, complication rates were 8.9% (95% CI 4.9% to 15.6%) thromboembolic and 8% (95% CI 4.3% to 14.2%) device-related. Complete angiographic occlusion after re-treatment was achieved in 64.1% (95% CI 52.6% to 74.2%), of patients, with 15.2% (95% CI 8.8% to 24.9%) requiring additional re-treatment. Conclusion Our review reports excellent safety and modest occlusion outcomes with re-treatment of recurrent or residual aneurysms post-WEB embolization. Outcomes with observational management of residual or recurrent aneurysms are lacking, questioning the requirement for re-treatment. Endovascular strategies demonstrated excellent safety and additional re-treatment rates, highlighting their expanding role in post-WEB recurrences.


  • Preliminary Experience Using Axolotl (Ambystoma mexicanum) Dermis Patches as a Biologic Agent for Wound Management After Neurosurgical Procedures

    by Megan D. Malueg, Ammad A. Baig, Matthew Moser, Brianna M. Donnelly, Justin Im, Jaims Lim, Bernard K. Okai, Steven B. Housley, Adnan H. Siddiqui, Kenneth V. Snyder